SHINPOONG PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,640 KRW | +2.10% |
|
+8.51% | +0.89% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| 2023 | South Korean Shares Continue Losing Streak Amid High Interest Rate Woes | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 319,310 | 359,254 | 6,353,533 | 1,653,859 | 1,124,818 | 707,263 |
| Enterprise Value (EV) 1 | 360,161 | 399,582 | 6,164,679 | 1,562,338 | 1,070,830 | 692,834 |
| P/E ratio | 115 x | 68 x | 1,307 x | -147 x | -31.9 x | -12.1 x |
| Yield | - | - | 0.08% | - | - | - |
| Capitalization / Revenue | 1.7 x | 1.89 x | 32.1 x | 8.74 x | 5.37 x | 3.53 x |
| EV / Revenue | 1.92 x | 2.11 x | 31.2 x | 8.26 x | 5.12 x | 3.46 x |
| EV / EBITDA | 18.8 x | 22.3 x | 309 x | -958 x | -50.5 x | -19.5 x |
| EV / FCF | 10.6 x | -257 x | 88 x | -32.1 x | -65.4 x | -25.9 x |
| FCF Yield | 9.47% | -0.39% | 1.14% | -3.12% | -1.53% | -3.86% |
| Price to Book | 1.51 x | 1.69 x | 16.8 x | 4.56 x | 3.29 x | 2.57 x |
| Nbr of stocks (in thousands) | 49,973 | 49,973 | 51,262 | 51,262 | 51,262 | 51,262 |
| Reference price 2 | 6,410 | 7,240 | 124,000 | 31,950 | 21,150 | 13,520 |
| Announcement Date | 3/21/19 | 3/23/21 | 3/23/21 | 3/17/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 187,389 | 189,722 | 197,751 | 189,237 | 209,288 | 200,229 |
| EBITDA 1 | 19,118 | 17,917 | 19,954 | -1,631 | -21,215 | -35,484 |
| EBIT 1 | 7,753 | 5,602 | 7,746 | -14,306 | -34,019 | -47,392 |
| Operating Margin | 4.14% | 2.95% | 3.92% | -7.56% | -16.25% | -23.67% |
| Earnings before Tax (EBT) 1 | 5,182 | 7,119 | 8,340 | -8,986 | -34,782 | -53,442 |
| Net income 1 | 2,804 | 5,324 | 5,003 | -11,584 | -35,377 | -57,325 |
| Net margin | 1.5% | 2.81% | 2.53% | -6.12% | -16.9% | -28.63% |
| EPS 2 | 55.50 | 106.5 | 94.85 | -217.8 | -663.9 | -1,118 |
| Free Cash Flow 1 | 34,118 | -1,552 | 70,074 | -48,674 | -16,386 | -26,774 |
| FCF margin | 18.21% | -0.82% | 35.44% | -25.72% | -7.83% | -13.37% |
| FCF Conversion (EBITDA) | 178.46% | - | 351.18% | - | - | - |
| FCF Conversion (Net income) | 1,216.87% | - | 1,400.69% | - | - | - |
| Dividend per Share | - | - | 100.0 | - | - | - |
| Announcement Date | 3/21/19 | 3/23/21 | 3/23/21 | 3/17/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 40,851 | 40,328 | - | - | - | - |
| Net Cash position 1 | - | - | 188,854 | 91,521 | 53,988 | 14,430 |
| Leverage (Debt/EBITDA) | 2.137 x | 2.251 x | - | - | - | - |
| Free Cash Flow 1 | 34,118 | -1,552 | 70,074 | -48,674 | -16,386 | -26,774 |
| ROE (net income / shareholders' equity) | 1.31% | 2.52% | 1.7% | -3.11% | -10.2% | -19% |
| ROA (Net income/ Total Assets) | 1.25% | 0.91% | 1.1% | -2.01% | -5.6% | -8.32% |
| Assets 1 | 225,131 | 587,424 | 454,099 | 577,333 | 632,183 | 688,618 |
| Book Value Per Share 2 | 4,247 | 4,281 | 7,396 | 7,008 | 6,430 | 5,259 |
| Cash Flow per Share 2 | 744.0 | 468.0 | 1,089 | 539.0 | 813.0 | 854.0 |
| Capex 1 | 1,792 | 12,074 | 2,654 | 4,425 | 5,323 | 14,888 |
| Capex / Sales | 0.96% | 6.36% | 1.34% | 2.34% | 2.54% | 7.44% |
| Announcement Date | 3/21/19 | 3/23/21 | 3/23/21 | 3/17/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.89% | 523M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A019170 Stock
- Financials Shinpoong Pharmaceutical Co.,Ltd
